|
Video: What is a Stock Split?
|
|
Harpoon Therapeutics is a clinical-stage immunotherapy company. Co.'s Tri-specific T cell Activating Construct (TriTACs) product candidates include: HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, which is for the treatment of multiple myeloma; and HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors. Co.'s proprietary TriTAC product candidate is HPN601, which targets the epithelial cell adhesion molecule and is being developed for the treatment of multiple solid tumor indications. According to our HARP split history records, Harpoon Therapeutics has had 1 split. | |
|
Harpoon Therapeutics (HARP) has 1 split in our HARP split history database. The split for HARP took place on September 05, 2023. This was a 1 for 10 reverse split, meaning for each 10 shares of HARP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Harpoon Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the HARP split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Harpoon Therapeutics shares, starting with a $10,000 purchase of HARP, presented on a split-history-adjusted basis factoring in the complete HARP split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/11/2019 |
|
End date: |
03/11/2024 |
|
Start price/share: |
$142.00 |
|
End price/share: |
$23.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-83.80% |
|
Average Annual Total Return: |
-30.11% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,620.74 |
|
Years: |
5.08 |
|
|
|
Date |
Ratio |
09/05/2023 | 1 for 10 |
|
|